CIPLA share price daily chart analysis
CIPLA share on last trading session closed at 375 with loss. On daily chart, stock price trend and momentum is down. CIPLA share had given downside breakout at 410 level and touched low of 370. Total 40-rupee rally was seen on lower side. From short-term view, CIPLA share support zones are 360 and 341 while on upside expect strong resistances at 382 and 400 levels. Daily chart indicators are bearish but off the lows so expect technical bounce back in prices because of short covering. Above 400 levels on closing basis expect fresh bull trend and then only buying is suggested with strict stop loss.
CIPLA share price weekly chart analysis
CIPLA share this week showing gains because of short covering at bottom. On weekly chart, stock price trend and momentum is down. From medium term view, CIPLA share below 410 on weekly closing basis remain sell on rise. On downside, 330 and 265 are major support zones and targets for this stock in current scenario. On upside above 410, medium term trend will change on bull’s side and expect resistances at 490 and then 570. As CIPLA share is fundamentally strong company, anything below 330 will be buying opportunity so watch for that.
CIPLA share price monthly chart analysis
CIPLA share is underperformer in last 6 month and given 5% negative return to investors. While as compared to major indices, it has given -22% return and disappointed investors. for long term investors, CIPLA below 250 rupee level will be value buying and on upside may targets are almost 600 rupee in next 3-5 years time frame for this stock. CIPLA is nifty 50 company from pharma sector and good for long-term investment at proper levels.
CIPLA Company information
Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure. In July 2013, the Company acquired Cipla Medpro South Africa Limited. In November 2013, the Company’s wholly owned step down subsidiary Meditab Holdings Limited, acquired an additional 14.5% interest in Quality Chemical Industries Limited (QCIL) and now held 51.05% interest in QCIL.
CIPLA share fundamental ratios
|Range||373.00 – 379.45|
|52 week||354.00 – 450.40|